Table 1.
Variable | Number | MST (days) | Survival rate (years) | P‐value | ||
---|---|---|---|---|---|---|
3 | 5 | 7 | ||||
Age (years) | ||||||
<65 | 21 | 3102 | 67 | 51 | 51 | .72 |
≥65 | 38 | 1644 | 64 | 41 | 36 | |
Gender | ||||||
Female | 11 | 1639 | 80 | 50 | 50 | .60 |
Male | 48 | 1339 | 61 | 42 | 38 | |
Alcohol abuse | ||||||
Presence | 13 | 1319 | 53 | 35 | 23 | .26 |
Absence | 46 | 1784 | 69 | 47 | 47 | |
Diabetes mellitus | ||||||
Presence | 17 | 1319 | 59 | 49 | 33 | .44 |
Absence | 42 | 1644 | 67 | 43 | 43 | |
Obesity | ||||||
Presence | 18 | 731 | 30 | 22 | 22 | <.01 |
Absence | 41 | 1996 | 75 | 54 | 49 | |
Dyslipidemia | ||||||
Presence | 12 | NA | 81 | 65 | 65 | .22 |
Absence | 47 | 1339 | 61 | 40 | 36 | |
Hypertension | ||||||
Presence | 26 | 1303 | 50 | 35 | 28 | .038 |
Absence | 33 | 3102 | 76 | 51 | 51 | |
HBc antibody | ||||||
Positive | 33 | 1639 | 74 | 43 | 43 | .61 |
Negative | 26 | 1784 | 52 | 46 | 39 | |
Interval from IFNa (years) | ||||||
≤5 | 39 | 1324 | 59 | 38 | 38 | .22 |
>5 | 20 | 1996 | 77 | 55 | 47 | |
T‐Bil (mg/dL) | ||||||
<1.0 | 48 | 1339 | 60 | 41 | 38 | .49 |
≥1.0 | 11 | 3102 | 82 | 53 | 53 | |
Albumin (g/dL) | ||||||
<4.0 | 14 | 1324 | 63 | 45 | 45 | .88 |
≥4.0 | 45 | 1644 | 65 | 44 | 40 | |
Platelet count (×104/mL) | ||||||
<15 | 29 | 1319 | 62 | 41 | 35 | .30 |
≥15 | 30 | 1784 | 68 | 48 | 48 | |
ALT (IU/L) | ||||||
>30 | 21 | 1784 | 68 | 46 | 46 | .42 |
≤30 | 38 | 1639 | 63 | 42 | 37 | |
α‐Fetoprotein (ng/mL) | ||||||
>20 | 17 | 1784 | 55 | 46 | 46 | .83 |
≤20 | 42 | 1639 | 69 | 43 | 38 | |
Tumor size (cm) | ||||||
>2.0 | 29 | 1303 | 54 | 45 | 45 | .93 |
≤2.0 | 30 | 1644 | 75 | 38 | 30 | |
Differentiation degreeb | ||||||
Well, mod | 45 | 1644 | 67 | 45 | 40 | .72 |
Poor | 14 | 1263 | 56 | 40 | 40 | |
No. tumors | ||||||
Single | 50 | 1784 | 67 | 48 | 44 | .075 |
Multiple | 9 | 945 | 50 | 17 | 17 | |
MVI | ||||||
Presence | 18 | 3102 | 59 | 59 | 59 | >.99 |
Absence | 41 | 1639 | 67 | 38 | 33 | |
Hepatic steatosis | ||||||
Positive | 32 | 1319 | 56 | 43 | 37 | .32 |
Negative | 27 | 1784 | 75 | 46 | 46 | |
Lobular inflammation | ||||||
Positive | 47 | NA | 62 | 41 | 41 | .37 |
Negative | 12 | 1324 | 75 | 64 | 54 | |
Ballooning | ||||||
Positive | 24 | 1324 | 59 | 39 | 31 | .33 |
Negative | 35 | 1644 | 69 | 47 | 47 | |
Liver cirrhosis | ||||||
Presence | 15 | 1028 | 44 | 44 | 44 | .37 |
Absence | 44 | 1644 | 72 | 44 | 40 | |
Type of hepatic resection | ||||||
Non‐anatomical | 37 | 1303 | 51 | 25 | 25 | .022 |
Anatomical | 22 | NA | 79 | 66 | 60 |
Interval from the end of interferon therapy to the detection of hepatocellular carcinoma.
Tumor differentiation: well, well‐differentiated; mod, moderately differentiated; poor, poorly differentiated.
ALT, alanine aminotransferase; HBc, hepatitis B core; IFN, interferon; MST, median survival time; MVI, microvascular invasion; NA, not applicable; T‐Bil, total bilirubin.